Clinical Core

临床核心项目摘要/摘要 临床核心是P30阿尔茨海默病研究中心(ADRC)的中心组成部分。这个 临床核心任务是提供资源，以促进中心在理解生物学方面的目标 阿尔茨海默病的途径。核心是与下列机构密切互动的共享资源：外展、 与招聘和培训有关的招聘和参与核心(ORE)核心；数据库 数据输入、存储和管理方面的管理和统计(DMS)核心； 神经病理学核心，通过安排脑部尸检并提供相关临床数据；以及 生物标志物、遗传学和神经免疫学核心，通过提供DNA、血浆、血细胞和 用于生物标志物、遗传学和免疫学分析的脑脊液样本。核心将建立在其 29年来，它是一个由P50资助的ADRC，在此期间，它招募了6000多人，近1900人 在NACC统一数据集(UDS)中--种族多样性，包括约20%的拉美裔和11%的拉美裔 非裔美国人。P30 Core将在一个新的队列中招募500人：每年100名新参与者， 其中正常对照组25例，轻度认知障碍或痴呆者75例。这些参与者 每个都将进行广泛的生物标记物研究，包括研究级3T磁共振成像和腰椎穿刺术 脑脊液检查，并每年进行跟踪。核心将向DMS核心提供数据，并传输 给国家阿尔茨海默氏症协调中心(NACC)，以及遗传学核心的DNA，送到国家 阿尔茨海默病中央资料库(NCRAD)。评估将包括详细的医疗和 神经学面谈和检查，以及神经心理测试，使用NACC和哥伦比亚网站- 特定的乐器。生物标记物将流向生物标记物、遗传学和神经免疫学核心，包括 血浆和外周血细胞群体的血液样本，用于遗传学研究的DNA准备，脑脊液 脊髓液细胞和液体生物标记物标本，以及3T磁共振神经成像。临床核心目标 包括死亡时的脑部尸检，以提供神经病理样本。核心坐标 与管理、生物标记物、DMS、ORE、遗传学、神经免疫学和神经病理学核心密切相关， 以及REC模块。向核心项目的参与者通报其他试验和项目，并鼓励他们 参与这些重要的成像、仪器、药物研究和生物标记物试验。临床核心提供 对学生、住院医生、研究员和调查人员进行培训。编码的参与者数据、图像和生物信息 样本，包括血浆，DNA，脑脊液和脑组织，与ADRC和其他哥伦比亚和 校外调查人员提高对衰老和痴呆症的诊断、了解和治疗，促进 哥伦比亚大学、纽约地区、全国和国际的基础和翻译研究。

CLINICAL CORE PROJECT SUMMARY/ABSTRACT The Clinical Core is the central component of the P30 Alzheimer’s Disease Research Center (ADRC). The Clinical Core mandate is to provide resources to further the goals of the Center in understanding biological pathways of Alzheimer’s Disease. The Core is a shared resource interacting closely with: the Outreach, Recruitment, and Engagement Core (ORE) Core with regard to recruitment and training; the Database Management and Statistical (DMS) Core with respect to data entry, storage and management; the Neuropathology Core, through arranging brain autopsy and providing relevant correlative clinical data; and the Biomarker, Genetics, and Neuroimmunology Cores through provision of DNA, plasma, blood cells, and cerebrospinal fluid samples for biomarker, genetic, and immunological analyses. The Core will build upon its 29 years as a funded P50 ADRC, during which time it has enrolled more than 6,000 individuals, nearly 1,900 of which are in the NACC Uniform Data Set (UDS) – with ethnic diversity including about 20% Hispanics and 11% African Americans. The P30 Core will enroll 500 individuals in a new cohort: 100 new participants per year, including 25 normal controls, and 75 persons with mild cognitive impairment or dementia. These participants will each have extensive biomarker studies including research-grade 3T MRI, and lumbar puncture for cerebrospinal fluid studies, and be followed annually. The Core will provide data to the DMS Core, transmitted to the National Alzheimer’s Coordinating Center (NACC), and DNA for the Genetics Core, sent to the National Centralized Repository for Alzheimer’s Disease (NCRAD). Evaluations will include detailed medical and neurological interviews and examinations and neuropsychological testing, using NACC and Columbia site- specific instruments. Biomarkers will flow to Biomarker, Genetics, and Neuroimmunology Cores, including blood samples for plasma and peripheral blood cell populations, DNA preparation for genetic studies, CSF specimens for spinal fluid cells and fluid biomarkers, and 3T MRI neuroimaging. The Clinical Core goals include brain autopsies at the time of death, to provide neuropathological samples. The Core coordinates closely with Administrative, Biomarkers, DMS, ORE, Genetics, Neuroimmunology, and Neuropathology Cores, and with the REC module. Participants in the Core are informed of other trials and projects, and encouraged to participate in these important imaging, instrument, drug study, and biomarker trials. The Clinical Core provides training to students, residents, fellows, and investigators. Coded participant data, images, and biological specimens, including plasma, DNA, CSF, and brain tissue are shared with ADRC, and other Columbia and extramural investigators to improve diagnosis, understanding and treatment of aging and dementia, promoting basic and translational research at Columbia, in the New York area, nationwide, and internationally.